Three senior executives exit Cipla's India unit

Cipla's India business has recently seen exits of three senior executives, including the head of the company's unit in the country.

The senior executives who have resigned are Nikhil Chopra, head of India business, Nikhil Lalwani, head of India prescription business, and Kunal Khanna, head of chronic and emerging therapies, according to a report by CNBC-TV18.

"They have served significant tenures in Cipla, we deeply value their contribution, respect their professional aspirations and wish them all the best. Cipla is a professionally run organisation with robust talent management and succession development processes. Our business momentum continues to be on strong footing and we are backed by a solid workforce of 23,000 employees who are driving Cipla in its next growth phase." Cipla said in a statement as seen by CNBC-TV18.

Also read: Coronavirus India | Cipla to soon launch COVID-19 drug Ciplenza at Rs 68 per tablet

Nikhil Chopra will be in charge of Cipla's India business until September 2020, the news channel reported. His direct reports will report to Cipla's Chief Executive Officer (CEO) Umang Vohra, until Chopra's replacement is appointed.

The exits will lead to a reshuffle of the senior management, the report added. Vikas Gupta will now head the Chronic cluster and will have the additional charge of Business Development and Portfolio.

Kamalesh Kalidasan will lead the Emerging cluster and Shaikh Barak Tulla will now be responsible for the Acute cluster, the report said.

Dilip Singh Rathore will head the Respiratory cluster, while Jortin George will lead the Alternate Channel Business and Sunil Gupta will remain in charge of the Gx business.